Clinical outcomes and costs for patients with type 2 diabetes mellitus initiating insulin therapy in Greece: Two-year experience from the INSTIGATE study

Primary Care Diabetes

Volumn 7, Issue 3, 2013, Pages 235-242

  Aloumanis, Kyriakos ^a   Benroubi, Marianna ^b   Sourmeli, Sotiria ^a   Drossinos, Vangelis ^a  

^a European Medical Research Institute by Pharmaserve Lilly   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

Cost; Diabetes; Insulin; Resources; Treatment

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG COST; DRUG SAFETY; FEMALE; GREECE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RESOURCE MANAGEMENT; TREATMENT OUTCOME; WEIGHT GAIN;

COST; DIABETES; INSULIN; RESOURCES; TREATMENT;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; BODY WEIGHT; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; FEMALE; GREECE; HEALTH RESOURCES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883825112     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2013.04.001     Document Type: Article

References (43)

1. I.M. Stratton, A.I. Adler, and H.A. Neil Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study British Medical Journal 321 2000 405 412
2. International Diabetes Federation. IDF Diabetes Atlas, fourth ed., 2009. http://www.diabetesatlas.org/ (accessed 20.08.10).
3. P.M. Clarke, P. Glasziou, and A. Patel Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis PLoS Medicine 7 2010 e1000236
4. E.H. Wagner, N. Sandhu, and K.M. Newton Effect of improved glycemic control on health care costs and utilization Journal of the American Medical Association 285 2001 181 189
5. L. Ettaro, T.J. Songer, P. Zhang, and M.M. Engelgau Cost-of-illness studies in diabetes mellitus Pharmacoeconomics 22 2004 149 164
6. A. Brown, L.R. Reynolds, and D. Bruemmer Intensive glycemic control and cardiovascular disease: an update Nature Reviews Cardiology 7 2010 369 375
7. The UK Prospective Diabetes Study Group UK prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease Diabetes 44 1995 1249 1258
8. M. Stolar Glycemic control and complications in type 2 diabetes mellitus American Journal of Medicine 123 2010 S3 S11
9. J.S. Skylar, R. Bergenstal, and R.O. Bonow Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 32 2009 187 192
10. J.L. Leahy Impaired beta-cell function with chronic hyperglycemic; "overworked beta-cell" hypothesis Diabetes Reviews 4 1996 298 319
11. The UK Prospective Diabetes Study Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
12. S.E. Inzucchi, R.M. Bergenstahl, and J.B. Buse Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 6 2012 1577 1596
13. I. Köster, L. von Ferber, and P. Ihle The cost burden of diabetes mellitus: the evidence from Germany-the CoDiM study Diabetologia 49 2006 1498 1504
14. A. Liebl, S. Jones, and M. Benroubi Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries Current Medical Research and Opinion 27 2011 887 895
15. M. Costi, H. Smith, and J. Reviriego Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study Endocrinology and Nutrition 58 2011 274 282
16. A. Liebl, L. Breitscheidel, C. Nicolay, and M. Happich Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study Current Medical Research and Opinion 24 2008 2349 2358
17. P. Muntner, C. Joyce, and E. Holt Defining the minimal detectable change in scores on the eight-item Morisky Medication Adherence Scale Annals of Pharmacotherapy 45 2011 569 575
18. K.A. Meadows, C. Abrams, and A. Sandbaek Adaptation of the Diabetes Health Profile (DHP-1) for use with patients with Type 2 diabetes mellitus: psychometric evaluation and cross-cultural comparison Diabetic Medicine 17 2000 572 580
19. T. Kohlmann, and J. Moock Patient satisfaction in diabetes mellitus - measures and results Deutsche Medizinische Wochenschrift 133 2008 S120 S123
20. H.W. Rodbard, P.S. Jellinger, and Davidson Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Pane l on type 2 diabetes mellitus: an algorithm for glycemic control Endocrine Practice 15 2009 540 559
21. National Institute for Health and Clinical Excellence Clinical Guideline G Management of type 2 diabetes London: NICE, Ref NO1288 (2002, Revised 2005).
22. European Diabetes Policy Group A desktop guide to type 2 diabetes mellitus Diabetic Medicine 16 1999 716 730
23. W.C. Hsu Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals Southern Medical Journal 102 2009 67 76
24. J.R. Sowers, and M. Epstein Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update Hypertension 26 1995 869 879
25. E.S. Moghissi Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes Mount Sinai Journal of Medicine 75 2008 558 566
26. M. Brod, J.H. Kongsø, S. Lessard, and T.L. Christensen Psychological insulin resistance: patient beliefs and implications for diabetes management Quality of Life Research 18 2009 23 32
27. L.S. Phillips, W.T. Branch, and C.B. Cook Clinical inertia Annals of Internal Medicine 135 9 2001 825 834
28. M.L. Parchman, J.A. Pugh, R.L. Romero, and K.W. Bowers Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin Annals of Family Medicine 5 3 2007 196 201
29. R. Grant, A.S. Adams, and C.M. Trinacty Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management Diabetes Care 30 4 2007 807 812
30. S. Jones, M. Benroubi, and C. Castell Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study Current Medical Research and Opinion 25 3 2009 691 700
31. J. Rosenstock Basal insulin supplementation in type 2 diabetes; refining the tactics American Journal of Medicine 116 2004 10S 16S
32. D.S. Lasserson, P. Glasziou, and R. Perera Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses Diabetologia 52 2009 1990 2000
33. M.J. Van Avendonk, and G.E. Rutten Insulin therapy in type 2 diabetes: what is the evidence? Diabetes, Obesity and Metabolism 11 2009 415 432
34. A. Liebl, S. Jones, and M. Benroubi Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries Current Medical Research and Opinion 27 5 2011 887 895
35. R. Qayyum, and L. Greene AHRQ's comparative effectiveness research on premixed insulin analogues for adults with type 2 diabetes: understanding and applying the systematic review findings Journal of Managed Care Pharmacy 17 2011 S3 S19
36. H. Ishii, M. Iwase, and H. Seino Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan Current Medical Research and Opinion 27 2011 643 650
37. A. Braun, A. Sämann, and T. Kubiak Effects of metabolic control, patient education and initiation of insulin therapy on the quality of life of patients with type 2 diabetes mellitus Patient Education and Counseling 73 2008 50 59
38. L.J. Lee, J.L. Fahrbach, and L.M. Nelson Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the durable trial Diabetes Research and Clinical Practice 89 2012 157 166
39. S. Liatis, P. Thomakos, and S. Papaoikonomou Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006) Experimental and Clinical Endocrinology and Diabetes 117 2009 505 510
40. K. Athanasakis, M. Ollandezos, and A. Angeli Estimating the direct cost of type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost Journal of Diabetes Medicine 27 2010 679 684
41. B. Jönsson Revealing the cost of Type II diabetes in Europe Diabetologia 45 2002 S5 S12
42. R.L. Kjome, A.G. Granas, and K. Nerhus The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nationwide cohort Diabetes Technology and Therapeutics 12 2010 701 705
43. S. Jones, C. Castell, and A. Goday Increase in direct diabetes-related costs and resource use in the 6 months following initiation of insulin in patients with type 2 diabetes in five European countries: data from the INSTIGATE study Clinicoeconomics and Outcomes Research 4 2012 383 393